An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Iveric Bio (NASDAQ: ISEE) announced on March 1, 2022 the grant of equity-based awards to four new non-executive employees under its 2019 Inducement Stock Incentive Plan. These grants included stock options for 72,000 shares and 500 restricted stock units, incentivizing employee acceptance of roles. The stock options have an exercise price of $16.10 per share, with a vesting schedule spanning four years. The restricted stock units vest fully on September 1, 2022, contingent upon continued employment.
Positive
Inducement grants incentivized hiring of four new employees.
Stock options priced at $16.10 align with market value, potentially motivating performance.
Negative
None.
PARSIPPANY, N.J.--(BUSINESS WIRE)--
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to four newly-hired, non-executive employees. These inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.
The inducement grants consisted of non-statutory stock options to purchase an aggregate of 72,000 shares of the Company’s common stock and an aggregate of 500 restricted stock units for shares of the Company’s common stock.
The stock options each have an exercise price of $16.10 per share, equal to the closing price of Iveric Bio’s common stock on March 1, 2022. The stock options each have a ten-year term and vest over four years, with 25% of the shares underlying each option vesting on March 1, 2023 and an additional 2.0833% of the shares underlying each option vesting at the end of each successive month thereafter. The grant of restricted stock units vests with respect to 100% of the shares underlying the applicable grant on September 1, 2022. The vesting of the grants is subject to the applicable employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.
Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
